SLS

MKT CAP:$636M

SELLAS Life Sciences Group, Inc.

Market Cap

$636M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.74+$0.39 (+8.85%)

Apr 23, 2026

Company Details

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a ...

CEO

Angelos Stergiou

IPO Date

Mar 12, 2008

Website

www.sellaslifesciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$27M

EPS (Diluted)

-$0.25

Free Cash Flow

-$28M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 19, 2026

$0EPS -$0.25

Q4 2025

Mar 19, 2026

$0EPS -$0.05

Q3 2025

Nov 12, 2025

$0EPS -$0.06

Q2 2025

Aug 12, 2025

$0EPS -$0.07

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$1M	$855.0K	-$7M
Q2 22	$0	$0	-$9M
Q3 22	$0	$0	-$7M
Q4 22	$0	-$123.0K	-$9M
Q1 23	$0	$0	-$11M
Q2 23	$0	$0	-$9M
Q3 23	$0	$0	-$9M
Q4 23	$0	$0	-$8M
Q1 24	$0	$0	-$10M
Q2 24	$0	$0	-$8M
Q3 24	$0	$0	-$7M
Q4 24	$0	$0	-$7M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$7M
Q3 25	$0	$0	-$7M
Q4 25	$0	$0	-$8M

Valuation

Quarter	P/S	P/E
Q1 22	39.2x	—
Q2 22	47.1x	—
Q3 22	42.0x	—
Q4 22	64.0x	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$7M	-$7M
Q2 22	-$6M	-$6M
Q3 22	-$6M	-$6M
Q4 22	-$5M	-$10M
Q1 23	-$12M	-$12M
Q2 23	-$8M	-$8M
Q3 23	-$7M	-$10M
Q4 23	-$5M	-$10M
Q1 24	-$11M	-$11M
Q2 24	-$10M	-$10M
Q3 24	-$8M	-$8M
Q4 24	-$7M	-$7M
Q1 25	-$9M	-$9M
Q2 25	-$7M	-$7M
Q3 25	-$7M	-$7M
Q4 25	-$5M	-$5M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$5M
Q1 23	$0
Q2 23	$0
Q3 23	$3M
Q4 23	$6M
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-82.5%	-2.6%
Q2 22	-100.0%	+35.7%
Q3 22	—	+2.4%
Q4 22	—	+59.6%
Q1 23	-100.0%	+45.8%
Q2 23	—	+5.0%
Q3 23	—	+31.0%
Q4 23	—	-13.4%
Q1 24	—	-14.5%
Q2 24	—	-15.8%
Q3 24	—	-21.7%
Q4 24	—	-15.4%
Q1 25	—	-37.1%
Q2 25	—	-9.8%
Q3 25	—	-3.4%
Q4 25	—	+19.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$375.0K	37.5%
Q2 22	$450.0K	—
Q3 22	$455.0K	—
Q4 22	$0	—
Q1 23	$540.0K	—
Q2 23	$514.0K	—
Q3 23	$543.0K	—
Q4 23	$497.0K	—
Q1 24	$476.0K	—
Q2 24	$334.0K	—
Q3 24	$381.0K	—
Q4 24	$373.0K	—
Q1 25	$505.0K	—
Q2 25	$501.0K	—
Q3 25	$503.0K	—
Q4 25	$447.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$5M	—	$3M
Q2 22	$6M	$3M	—
Q3 22	$4M	$3M	—
Q4 22	$6M	—	$3M
Q1 23	$7M	$4M	—
Q2 23	$6M	$3M	—
Q3 23	$6M	$4M	—
Q4 23	$5M	$3M	—
Q1 24	$5M	$5M	—
Q2 24	$5M	$2M	—
Q3 24	$4M	$3M	—
Q4 24	$4M	$2M	—
Q1 25	$3M	$3M	—
Q2 25	$4M	$3M	—
Q3 25	$4M	$3M	—
Q4 25	$5M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$14M	$0	$14M
Q2 22	$27M	$0	$27M
Q3 22	$21M	$0	$21M
Q4 22	$17M	$0	$17M
Q1 23	$24M	$0	$24M
Q2 23	$14M	$0	$14M
Q3 23	$4M	$0	$4M
Q4 23	$3M	$0	$3M
Q1 24	$18M	$0	$18M
Q2 24	$9M	$0	$9M
Q3 24	$21M	$0	$21M
Q4 24	$14M	$0	$14M
Q1 25	$28M	$0	$28M
Q2 25	$25M	$0	$25M
Q3 25	$44M	$0	$44M
Q4 25	$72M	$0	$72M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	16M	+0.0%	+6.9%
Q2 22	20M	+27.6%	+32.9%
Q3 22	21M	+1.4%	+29.5%
Q4 22	21M	+1.1%	+30.8%
Q1 23	24M	+13.3%	+48.1%
Q2 23	28M	+20.4%	+39.7%
Q3 23	28M	+0.0%	+37.9%
Q4 23	31M	+8.6%	+48.2%
Q1 24	45M	+45.5%	+90.3%
Q2 24	58M	+28.6%	+103.3%
Q3 24	68M	+18.4%	+140.7%
Q4 24	74M	+8.4%	+140.2%
Q1 25	88M	+18.6%	+95.8%
Q2 25	99M	+12.3%	+71.0%
Q3 25	108M	+10.0%	+58.8%
Q4 25	153M	+41.2%	+106.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$90.9K	11
Q2 22	$0	11
Q3 22	$0	11
Q4 22	$0	17
Q1 23	$0	17
Q2 23	$0	17
Q3 23	$0	17
Q4 23	$0	16
Q1 24	$0	16
Q2 24	$0	16
Q3 24	$0	16
Q4 24	$0	15
Q1 25	$0	15
Q2 25	$0	15
Q3 25	$0	15
Q4 25	$0	200K

Revenue / Employee